Who
J. Matthew Singleton
Director
Company insider
Files Form 4 as: Director, Viking Therapeutics; Director, Cubist Pharmaceuticals.
In numbers
- Trades disclosed
- 77
- Buys
- 1
- Sells
- 13
- Bought
- $93K
- Sold
- $6.9M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 8 Jun 2006
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,800 at $0.00 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,000 at $0.00 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $72K16,000 at $4.48 | filing |
| 25 Oct 2024filed 25 Oct 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M16,000 at $79.50 | filing |
| 20 Sep 2024filed 20 Sep 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,300 at $0.00 | filing |
| 20 Sep 2024filed 20 Sep 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $12K10,300 at $1.19 | filing |
| 20 Sep 2024filed 20 Sep 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $716K10,300 at $69.50 | filing |
| 21 Aug 2024filed 22 Aug 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,700 at $0.00 | filing |
| 21 Aug 2024filed 22 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,7835,700 at $1.19 | filing |
| 21 Aug 2024filed 22 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $397K5,700 at $69.72 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,000 at $0.00 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code M | $53K16,000 at $3.33 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $150K2,500 at $60.01 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $186K3,047 at $61.13 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $279K4,509 at $61.86 | filing |
| 19 Aug 2024filed 19 Aug 2024 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $130K2,055 at $63.15 | filing |
News
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026Viking Therapeutics (NASDAQ:VKTX) Hits New 52-Week Low – Time to Sell?VKTX · dailypolitical.com · 14 Oct 2026Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityVKTX · finanznachrichten.de · 14 Oct 2026
0 headlines in the last 90 days name J. Matthew Singleton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.